EP2809675A4 - Rafamycin analogs and methods for making same - Google Patents
Rafamycin analogs and methods for making sameInfo
- Publication number
- EP2809675A4 EP2809675A4 EP12889107.4A EP12889107A EP2809675A4 EP 2809675 A4 EP2809675 A4 EP 2809675A4 EP 12889107 A EP12889107 A EP 12889107A EP 2809675 A4 EP2809675 A4 EP 2809675A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- rafamycin
- analogs
- methods
- making same
- making
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/085631 WO2014082286A1 (en) | 2012-11-30 | 2012-11-30 | Rafamycin analogs and methods for making same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2809675A1 EP2809675A1 (en) | 2014-12-10 |
EP2809675A4 true EP2809675A4 (en) | 2015-08-12 |
Family
ID=50827071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12889107.4A Withdrawn EP2809675A4 (en) | 2012-11-30 | 2012-11-30 | Rafamycin analogs and methods for making same |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2809675A4 (en) |
JP (1) | JP2016500112A (en) |
KR (1) | KR20150003156A (en) |
CN (1) | CN104854112A (en) |
AU (1) | AU2012395673A1 (en) |
CA (1) | CA2863243A1 (en) |
SG (1) | SG11201404432QA (en) |
WO (1) | WO2014082286A1 (en) |
ZA (1) | ZA201405746B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327097B (en) * | 2014-10-11 | 2017-02-08 | 福建省微生物研究所 | Triazole derivatives of rapamycin and application |
CN104341434B (en) * | 2014-10-16 | 2016-04-06 | 福建省微生物研究所 | The rapamycin triazole derivatives replaced and purposes |
CN104557975B (en) * | 2014-12-23 | 2017-06-20 | 连云港恒运医药有限公司 | The preparation method of everolimus intermediate and its degradation impurity |
EP3061765B1 (en) * | 2015-02-27 | 2018-01-31 | Warszawski Uniwersytet Medyczny | Protoescigenin derivative, process of its preparation, use of said compound and pharmaceutical composition comprising that compound |
CN104876944B (en) * | 2015-05-13 | 2017-11-10 | 普济生物科技(台州)有限公司 | A kind of preparation method of everolimus |
EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
WO2017038925A1 (en) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin or derivative thereof |
CN105481704A (en) * | 2016-01-12 | 2016-04-13 | 西安近代化学研究所 | Method for synthesis and purification of bonding agent N-propargyl diethanol amine |
CN107759616B (en) * | 2016-08-23 | 2020-11-17 | 上海微创医疗器械(集团)有限公司 | Compound and preparation method and application thereof |
IL288991B2 (en) * | 2017-04-05 | 2023-12-01 | Harvard College | Macrocyclic compound and uses thereof |
AU2018263886C1 (en) * | 2017-05-02 | 2022-12-22 | Revolution Medicines, Inc. | Rapamycin analogs as mTOR inhibitors |
CN109776569A (en) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | A kind of preparation method of everolimus |
CN108484637A (en) * | 2018-03-13 | 2018-09-04 | 福建省微生物研究所 | Target anticancer new drug X-76 salt-forming compounds and application thereof, preparation method |
IL278335B1 (en) | 2018-05-01 | 2024-05-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as mtor inhibitors |
ES2945560T3 (en) | 2018-05-01 | 2023-07-04 | Revolution Medicines Inc | Rapamycin analogues linked at C40, C28 and C-32 as mTOR inhibitors |
CN109776571B (en) * | 2019-01-31 | 2021-06-11 | 哈药慈航制药股份有限公司 | Rapamycin analogue and preparation method and application thereof |
CN112057425A (en) * | 2020-09-30 | 2020-12-11 | 严鹏科 | Rapamycin preparation and preparation method thereof |
CN115160343B (en) * | 2022-06-09 | 2023-11-14 | 福建省微生物研究所 | Rapamycin derivative, and preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
CN1235608A (en) * | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | Alkylated reapamycin derivatives |
AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
TW557297B (en) * | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
-
2012
- 2012-11-30 SG SG11201404432QA patent/SG11201404432QA/en unknown
- 2012-11-30 AU AU2012395673A patent/AU2012395673A1/en not_active Abandoned
- 2012-11-30 WO PCT/CN2012/085631 patent/WO2014082286A1/en active Application Filing
- 2012-11-30 CN CN201280077424.7A patent/CN104854112A/en active Pending
- 2012-11-30 EP EP12889107.4A patent/EP2809675A4/en not_active Withdrawn
- 2012-11-30 CA CA2863243A patent/CA2863243A1/en not_active Abandoned
- 2012-11-30 JP JP2015544291A patent/JP2016500112A/en active Pending
- 2012-11-30 KR KR20147024024A patent/KR20150003156A/en not_active Application Discontinuation
-
2014
- 2014-08-04 ZA ZA2014/05746A patent/ZA201405746B/en unknown
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2014082286A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN104854112A (en) | 2015-08-19 |
WO2014082286A1 (en) | 2014-06-05 |
KR20150003156A (en) | 2015-01-08 |
AU2012395673A1 (en) | 2014-08-14 |
CA2863243A1 (en) | 2014-06-05 |
AU2012395673A8 (en) | 2015-06-11 |
WO2014082286A9 (en) | 2014-11-13 |
ZA201405746B (en) | 2015-11-25 |
EP2809675A1 (en) | 2014-12-10 |
SG11201404432QA (en) | 2014-10-30 |
JP2016500112A (en) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250690A1 (en) | Methods | |
ZA201405746B (en) | Rafamycin analogs and methods for making same | |
HK1208363A1 (en) | New methods | |
GB201212937D0 (en) | Method | |
GB201212932D0 (en) | Method | |
GB201213636D0 (en) | Method | |
GB201212934D0 (en) | Method | |
GB201210858D0 (en) | Method | |
GB2507760B (en) | Methods | |
EP2880048A4 (en) | Method | |
GB201218570D0 (en) | Method | |
GB201208874D0 (en) | Methods | |
GB201202198D0 (en) | Method | |
GB201211393D0 (en) | Method | |
GB201204280D0 (en) | Methods | |
GB201217688D0 (en) | Method | |
GB201214029D0 (en) | method | |
GB201210147D0 (en) | Method | |
GB201208756D0 (en) | Methods | |
GB201213858D0 (en) | Method | |
GB201203337D0 (en) | Method | |
GB201201332D0 (en) | Method | |
EP2639418A4 (en) | Exhaust-heating method | |
GB201220686D0 (en) | Methods | |
AP2012000550S (en) | E-horn methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150710 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 498/18 20060101AFI20150706BHEP Ipc: A61P 35/00 20060101ALI20150706BHEP Ipc: A61K 31/436 20060101ALI20150706BHEP Ipc: A61P 37/00 20060101ALI20150706BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170601 |